CoChat

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy

Open access
Komdeur, Fenne L., Wouters, Maartje C.A., Workel, Hagma H., Tijans, Aline M., Terwindt, Anouk L.J., Brunekreeft, Kim L., Plat, Annechien, Klip, Harry G., Eggink, Florine A., Leffers, Ninke, Helfrich, Wijnand, Samplonius, Douwe F., Bremer, Edwin, Wisman, G. Bea A., Daemen, Toos, Duiker, Evelien W., Hollema, Harry, Nijman, Hans W., de Bruyn, Marco · 2016 · Oncotarget
Cited by 69

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

// Fenne L. Komdeur 1, * , Maartje C.A. Wouters 1, 2, * , Hagma H. Workel 1 , Aline M. Tijans 1 , Anouk L.J. Terwindt 1 , Kim L. Brunekreeft 1 , Annechien Plat 1 , Harry G. Klip 1 , Florine A. Eggink 1 , Ninke Leffers 1 , Wijnand Helfrich 3 , Douwe F. Samplonius 3 , Edwin Bremer 3 , G. Bea A. Wisman 1 , Toos Daemen 2 , Evelien W. Duiker 4 , Harry Hollema 4 , Hans W. Nijman 1, # , Marco de Bruyn 1, # 1 University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands 2 University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, The Netherlands 3 University of Groningen, University Medical Center Groningen, Department of Surgery, The Netherlands 4 University of Groningen, University Medical Center Groningen, Department of Pathology, The Netherlands * These authors have contributed equally to this work # MB and HWN share senior authorship Correspondence to: Hans W. Nijman, email: h.w.nijman@umcg.nl Keywords: tumor-infiltrating lymphocytes, high-grade serous ovarian cancer, CD103, TGF-β, cancer immunotherapy Received: May 06, 2016 Accepted: September 02, 2016 Published: September 16, 2016 ABSTRACT CD103+ tumor-infiltrating lymphocytes (TIL) have been linked to specific epithelial infiltration and a prolonged survival in high-grade serous epithelial ovarian cancer (HGSC). However, whether these cells are induced as part of an ongoing anti-HGSC immune response or represent non-specifically expanded resident or mucosal lymphocytes remains largely unknown. In this study, we first confirmed that CD103+ TIL from HGSC were predominantly localized in the cancer epithelium and were strongly correlated with an improved prognosis. We further demonstrate that CD103+ TIL were almost exclusively CD3+ TCRαβ+ CD8αβ+ CD4- T cells, but heterogeneously expressed T cell memory and differentiation markers. Activation of peripheral T cells in the presence of HGSC was sufficient to trigger induction of CD103 in over 90% of all CD8+ cells in a T cell receptor (TCR)- and TGFβR1-dependent manner. Finally, CD103+ TIL isolated from primary HGSC showed signs of recent activation and dominantly co-expressed key immunotherapeutic targets PD-1 and CD27. Taken together, our data indicate CD103+ TIL in HGSC are formed as the result of an adaptive anti-tumor immune response that might be reactivated by (dual) checkpoint inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12077

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 69

Metadata

Authors
Komdeur, F. L., Wouters, M. C. A., Workel, H. H., Tijans, A. M., Terwindt, A. L. J., Brunekreeft, K. L., Plat, A., Klip, H. G., Eggink, F. A., Leffers, N., Helfrich, W., Samplonius, D. F., Bremer, E., Wisman, G. B. A., Daemen, T., Duiker, E. W., Hollema, H., Nijman, H. W., & de Bruyn, M.
Venue
Oncotarget
Published
2016-09-16
Volume
7
Issue
46
Pages
75130-75144
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2519636301
Cited by
69
References
2
FWCI
8.24
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.